Opko Health Inc
$ 1.42
-2.07%
12 Jun - close price
- Market Cap 1,094,884,000 USD
- Current Price $ 1.42
- High / Low $ 1.48 / 1.42
- Stock P/E N/A
- Book Value 1.67
- EPS -0.27
- Next Earning Report 2026-07-30
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.17 %
- 52 Week High 1.60
- 52 Week Low 0.98
About
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
Analyst Target Price
$3.76
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-28 | 2026-02-26 | 2025-10-29 | 2025-07-31 | 2025-04-30 | 2025-02-27 | 2024-11-07 | 2024-08-07 | 2024-05-07 | 2024-02-27 | 2023-11-06 | 2023-08-03 |
| Reported EPS | -0.07 | -0.0358 | 0.03 | -0.08 | -0.09 | 0.01 | 0.03 | -0.01 | -0.12 | -0.09 | -0.11 | -0.03 |
| Estimated EPS | -0.07 | -0.0671 | -0.04 | -0.1 | -0.11 | -0.1 | -0.09 | -0.09 | -0.09 | -0.09 | -0.1 | -0.07 |
| Surprise | 0 | 0.0313 | 0.07 | 0.02 | 0.02 | 0.11 | 0.12 | 0.08 | -0.03 | 0 | -0.01 | 0.04 |
| Surprise Percentage | 0% | 46.6468% | 175% | 20% | 18.1818% | 110% | 133.3333% | 88.8889% | -33.3333% | 0% | -10% | 57.1429% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-07-30 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OPK
2026-06-09 19:38:58
This article identifies three promising penny stocks with market caps over $20 million, highlighting OPKO Health (OPK), Sight Sciences (SGHT), and Nu Ride (NRDE). It details their financial health, operational segments, and recent performance, suggesting they offer potential value and growth for investors seeking under-the-radar companies. Each company's overview includes its market cap, financial challenges or strengths, and future prospects.
2026-06-09 11:09:10
This article highlights three penny stocks—OPKO Health (OPK), Sight Sciences (SGHT), and Nu Ride (NRDE)—that demonstrate promising financial strength despite the recent market drop. Each company is analyzed for its operational performance, market capitalization, and financial health, including aspects like revenue growth, debt levels, and profitability challenges. The piece aims to guide investors looking for undervalued companies with long-term growth potential in the smaller market cap segment.
2026-06-07 07:10:32
This article analyzes the recent stock performance of OPKO Health (OPK), which has seen a 17.1% increase since its last earnings report. Investors are now questioning whether this upward trend can be sustained, suggesting a focus on future growth prospects and financial results.
2026-06-06 18:39:56
OPKO Health has strengthened its partnership with Nicoya Therapeutics to accelerate the commercialization of RAYALDEE in Greater China, acquiring an equity interest in Nicoya. This alliance aims to leverage the vast renal health market in the region, with OPKO focusing on regulatory and commercial progress. Investors are advised to monitor regulatory milestones and financial disclosures related to this collaboration, as OPKO is currently not profitable.
2026-06-06 06:09:28
OPKO Health (OPK) has amended its partnership with Nicoya Therapeutics, gaining a 15% equity interest in the firm to further commercialize RAYALDEE in Greater China. This adjustment modifies the royalty and transfer price schedule, while OPKO Health remains eligible for up to $115 million in potential development, regulatory, and sales-based milestone payments. The collaboration aims to expand patient access to RAYALDEE for treating chronic kidney disease in the large Asian renal health market, with regulatory approvals targeted for 2027 across China and its related territories.
2026-06-05 21:39:14
OPKO Health has amended its partnership agreement with Nicoya Therapeutics, acquiring a 15% equity interest in the company. This move deepens their collaboration to commercialize RAYALDEE in Greater China, aiming for regulatory approvals across China and related territories by 2027 to address chronic kidney disease. The agreement also maintains OPKO's eligibility for up to $115 million in potential milestone payments.
